Latest News

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

These new data on spesolimab (Spevigo) in adults with generalized pustular psoriasis highlight long-term findings with the treatment.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

The FDA has approved a labeling update for 1 mg epinephrine nasal spray permitting use in any patient weighing 33 lbs or more.

A post-hoc analysis of phase 3 trials found tapinarof cream 1% produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

Geara breaks down the clinical framework for the modern era of IgA nephropathy.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Hear Martha Gulati, MD, MS, reveal how mentorship and have shaped her career in women’s heart care.

This release by Apogee Therapeutics highlights findings from the phase 2 APEX trial on zumilokibart (APG777) in adults with moderate to severe atopic dermatitis.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.

Phase 3b ENCORE shows inhaled ARIKAYCE boosts culture conversion and symptoms in antibiotic‑naïve MAC lung disease, paving way for 2026 label expansion.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

In this Q&A, Linda Stein Gold, MD, shares her views on the clinical significance of icotrokinra's FDA approval and the data leading to this approval.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new phase 3 data, in this week’s essential news roundup.

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.